The role of implantable cardiac defibrillators in cardiac sarcoidosis: Saviour or sinner?

Europace

Volumn 15, Issue 3, 2013, Pages 309-310

  Heck, Patrick M ^a   Roberts, Paul R ^b  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; CARDIAC SARCOIDOSIS; CLINICAL EFFECTIVENESS; COMPLETE HEART BLOCK; EDITORIAL; HEART EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PRIMARY PREVENTION; PRIORITY JOURNAL; SAFETY; SARCOIDOSIS; TREATMENT INDICATION;

CARDIOMYOPATHIES; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; PRIMARY PREVENTION; SARCOIDOSIS; SECONDARY PREVENTION; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 84874439732     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eus406     Document Type: Editorial

References (11)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and theWorld Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.
2. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995;119:167-72.
3. Iwai K, Sekiguti M, Hosoda Y, DeRemee RA, Tazelaar HD, Sharma OP et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994; 11:26-31.
4. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008;5:e1-62.
5. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 2013;15:347-54.
6. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012;23:925-9.
7. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;9:884-91.
8. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
9. Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: Role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 2011;4:43-8.
10. Aizer A, Stern EH, Gomes JA, Teirstein AS, Eckart RE, Mehta D. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol 2005;96:276-82.
11. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK et al. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63(Suppl. 5):v1-58.